Children's Oncology Group's 2023 blueprint for research: Rare tumors

The Children's Oncology Group (COG) Rare Tumor Committee includes the Infrequent Tumor and Retinoblastoma subcommittees, encompassing a wide range of extracranial solid tumors that do not fall within another COG disease committee. Current therapeutic trial development focuses on nasopharyngeal carcinoma, adrenocortical carcinoma, pleuropulmonary blastoma, colorectal carcinoma, melanoma, and thyroid carcinoma. Given the rarity of these tumors, novel strategies and international collaborative efforts are necessary to advance research and improve outcomes.

Automated summary

The Children's Oncology Group (COG) Rare Tumor Committee focuses on a wide range of extracranial solid tumors that are not covered by other COG disease committees. Current therapeutic trials are targeting various rare tumors such as nasopharyngeal carcinoma, adrenocortical carcinoma, and melanoma. Collaborative efforts and novel strategies are essential for advancing research and improving outcomes in these rare tumors.